Navigation Links
CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Date:8/14/2008

- Awards recognize innovative biopharmaceutical drugs and devices that have

made a deep impact on the quality of human life -

PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that its chronic angina therapy Ranexa(R) (ranolazine extended-releases tablets) has been selected as a finalist for the prestigious Prix Galien USA 2008 award which honors the best pharmaceutical agent and best biotechnology product of the year. Winners will be announced on September 24, 2008 in New York.

"Being named a finalist for the Prix Galien USA awards is a great honor. We congratulate the dedicated employees, researchers and physicians who make it possible for this important medicine to help patients every day," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.

The Prix Galien USA Awards committee of 11, including seven Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development.

About Ranexa(R)

In the United Sates, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. In Europe, ranolazine is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
2. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
11. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 09, 2016 , ... PharmApprove announced today the ... Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with ... the drug regulatory review process. , “Adding Diane Dorman is just the latest ...
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Board of Directors. Todorow is the Executive Vice President for Corporate Services and ... Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply ...
Breaking Biology Technology:
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
Breaking Biology News(10 mins):